Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    公开(公告)号:US10246508B2

    公开(公告)日:2019-04-02

    申请号:US15122241

    申请日:2015-03-04

    申请人: CHEMOMAB LTD.

    发明人: Adi Mor

    摘要: Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

    Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

    公开(公告)号:US10479830B2

    公开(公告)日:2019-11-19

    申请号:US16270231

    申请日:2019-02-07

    申请人: CHEMOMAB LTD.

    发明人: Adi Mor

    IPC分类号: C07K16/24 A61K39/00

    摘要: The invention concerns isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2, whereby the antibodies bind additional CCR3-binding chemokines. The invention further concerns use of these antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

    ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES
    10.
    发明申请
    ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES 审中-公开
    识别额外的CCR3结合蛋白的抗爱立新-2抗体

    公开(公告)号:US20160368979A1

    公开(公告)日:2016-12-22

    申请号:US15122241

    申请日:2015-03-04

    申请人: CHEMOMAB LTD.

    发明人: Adi MOR

    IPC分类号: C07K16/24

    摘要: Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

    摘要翻译: 提供了针对趋化因子嗜酸性粒细胞趋化因子2中唯一表位的分离的多特异性抗体。该抗体结合额外的CCR3结合趋化因子。 还提供了使用抗体减弱各种细胞的迁移和治疗纤维化疾病,自身免疫性炎性疾病,单核细胞相关病症或过敏性特应性疾病的方法。